Proteomic analysis of clear cell renal cell carcinoma: Identification of potential tumor markers

Saudi Medical Journal

Volumn 31, Issue 5, 2010, Pages 525-532

  Sun, Chuan Y ^a   Zang, Ya C ^a   San, Yu X ^a   Sun, Wei ^a   Zhang, Liang ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL LIPASE; ADENINE NUCLEOTIDE TRANSLOCASE; ALCOHOL DEHYDROGENASE; AMMECR1 LIKE PROTEIN; CALBINDIN; CD2 ASSOCIATED PROTEIN; GLUTATHIONE TRANSFERASE P1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEUCINE TYROSINE ARGININE MOTIF CONTAINING PROTEIN 5; LIPOCORTIN 5; LIQUID NITROGEN; NEURON SPECIFIC ENOLASE; PEROXIREDOXIN 6; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINAL DEHYDROGENASE; THIOREDOXIN DEPENDENT PEROXIDE REDUCTASE; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN; PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CHINA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; UPREGULATION; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77954059797     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Banks RE, Craven RA, Harnden P, Madaan S, Joyce A, Selby PJ. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007; 25: 537-556.
2. Guo F, Nian H, Zhang H, Huang L, Tang Y, Xiao X, et al. Proteomic analysis of the transition from quiescent to proliferating stages in rat liver hepatectomy model. Proteomics 2006; 6: 3075-3086.
3. Matrix Science [homepage on the internet]. Available from:-
4. Amato RJ. Renal cell carcinoma: review of novel singleagent therapeutics and combination regimens. Ann Oncol 2005; 16: 7-15.
5. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, et al. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 2005; 20: 450-455.
6. Tsukamoto Y, Tsuchiya AS, Namikawa T, Tatesaki R, Adachi K, Hiroi S, et al. Expression of calbindin-D28K in sporadic nephroblastomas of the chicken. Avian Dis 2006; 50: 127-130.
7. Martignoni G, Pea M, Chilosi M, Brunelli M, Scarpa A, Colato C, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol 2001; 14: 760-767.
8. Landriscina M, Altamura SA, Roca L, Gigante M, Piscazzi A, Cavalcanti E, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008; 122: 2842-2850.
9. Verrier F, Mignotte B, Jan G, Brenner C. Study of PTPC composition during apoptosis for identification of viral protein target. Ann N Y Acad Sci 2003; 1010: 126-142.
10. Zamarin D, García-Sastre A, Xiao X, Wang R, Palese P. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog 2005; 1: e4.
11. Zamora M, Ortega JA, Alaña L, Viñas O, Mampel T. Apoptotic and anti-proliferative effects of all-trans retinoic acid. Adenine nucleotide translocase sensitizes HeLa cells to all-trans retinoic acid. Exp Cell Res 2006; 312: 1813-1819.
12. Hu Z, Guo X, Yu Q, Qiu L, Li J, Ying K, et al. Down-regulation of adenine nucleotide translocase 3 and its role in camptothecininduced apoptosis in human hepatoma QGY7703 cells. FEBS Lett 2009; 583: 383-388.
13. Denko N, Schindler C, Koong A, Laderoute K, Green C, Giaccia A. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res 2000; 6: 480-487.
14. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13: 7388-7393.
15. Di Cristofano C, Minervini A, Menicagli M, Salinitri G, Bertacca G, Pefanis G, et al. Nuclear expression of hypoxiainducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol 2007; 31: 1875-1881.
16. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, et al. Overcoming glutathione S-transferase P1- related cisplatin resistance in osteosarcoma. Cancer Res 2008; 68: 6661-6668.
17. Yu DS, Ma CP, Chang SY. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance. Urol Res 2000; 28: 86-92.
18. Masaki M, Ikeda A, Shiraki E, Oka S, Kawasaki T. Mixed lineage kinase LZK and antioxidant protein-1 activate NFkappaB synergistically. Eur J Biochem 2003; 270: 76-83.
19. Soini Y, Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang SW, et al. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. APMIS 2006; 114: 329-337.
20. Schremmer B, Manevich Y, Feinstein SI, Fisher AB. Peroxiredoxins in the lung with emphasis on peroxiredoxin VI. Subcell Biochem 2007; 44: 317-344.
21. Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
22. Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005; 5: 1024-1032.
23. Nisman B, Biran H, Ramu N, Heching N, Barak V, Peretz T. The diagnostic and prognostic value of ProGRP in lung cancer. Anticancer Res 2009; 29: 4827-4832.
24. Savvateeva EN, Dementieva EI, Tsybulskaya MV, Osipova TV, Ryabykh TP, Turygin AY, et al. Biological microchip for a simultaneous quantitative immunoassay of tumor markers in human serum. Bull Exp Biol Med 2009; 147: 737-741.
25. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-1153.
26. Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, et al. Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene 2007; 26: 1661-1672.
27. Geramizadeh B, Ravanshad M, Rahsaz M. Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma. Indian J Pathol Microbiol 2008; 51: 167-171.
28. Huang W, Kanehira K, Drew S, Pier T. Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study. Appl Immunohistochem Mol Morphol 2009; 17: 12-17.
29. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007; 26: 2563-2573.
30. Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 2007; 10: 144-151.
31. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hemstreet GP 3rd. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 2000; 89: 412-423.